Reengineering medicines development: a stakeholder discussion document for cost-effective development of affordable innovative medicines was launched at an ABPI roundtable event March 4, 2015, and includes a suggested methodology to increase the relevance of clinical trials while substantially reducing timelines and costs. With the potential to bring innovative medicines to patients more quickly with improved value and cost effectiveness, this will only be possible through partnership working between patients, healthcare providers and practitioners, Health Technology Assessment bodies and payers, regulatory authorities and the pharmaceutical industry. More information and the full report are available on the ABPI website, here.